Thank you for joining us at CIRSE 2022

Thank you for attending CIRSE 2022

It was a great opportunity to share our innovative portfolio and associated scientific evidence and show how it can support you and your patients in individualizing each treatment in order to improve outcomes, while ensuring economic value to the healthcare system.

Take the opportunity to learn how we support the

building of evidence in treating HCC patients with the Holmium Platform with our chairmen, Prof. J. Ricke and Dr. I. Bargellini and panel of experts, Prof. G. Verset, Prof. M. Lam, Dr. L. Tsilikas. Learn more about our key trials in SIRT from HEPAR Primary to HOLMBRAVE, passing by RETOUCH and HOMIE-166

Watch the replay

Watch the on-demand lectures on TACE with LifePearl^TM and thermal ablation with TATO

Artery-first microwave ablation in the treatment of benign thyroid nodules - G. Yildirim et al.
Early and long-term effectiveness results from CIREL, the multi-centre observational study on irinotecan- TACE in CRLM - P. Pereira et al.

Rising to the challenge of creating innovative

treatments for patients, we bring you a complete

range of interventional oncology products that focus on target lesion access, loco-regional treatments and endovascular embolization.

Not all products are available for sale in all countries. This information is provided only in respect to markets where these products are approved or cleared. Not all products are cleared or approved in the U.S.A. by the Food and Drug Administration. Please contact your Terumo local sales representative for more information.

Legal and privacy policy

Thank you for attending CIRSE 2022

Watch the on-demand lectures on TACE with LifePearlTM and thermal ablation with TATO

Watch the on-demand lectures on TACE with LifePearl^TM and thermal ablation with TATO